MEK5 promotes lung adenocarcinoma

Eur Respir J. 2019 Feb 28;53(2):1801327. doi: 10.1183/13993003.01327-2018. Print 2019 Feb.

Authors

Adrián Sánchez-Fdez^{1

2

3}, María Jesús Ortiz-Ruiz^{1

2}, María Florencia Re-Louhau^{1

2}, Isabel Ramos¹, Óscar Blanco-Múñez^{2

4}, Dolores Ludeña^{2

4}, Mar Abad^{2

4}, Manuel Sánchez-Martín^{3

5}, Atanasio Pandiella^{1

2

3}, Azucena Esparís-Ogando^{1

2

3}

Affiliations

¹ Instituto de Biología Molecular y Celular del Cáncer-CSIC, Salamanca, Spain.
² IBSAL, Salamanca, Spain.
³ CIBERONC, Salamanca, Spain.
⁴ Pathology Service, University Hospital, Salamanca, Spain.
⁵ Transgenic Facility of the Nucleus Platform, University of Salamanca, Salamanca, Spain.

Abstract

MEK5 acts as an oncogenic driver in mice lung cancer and is pivotal for human lung adenocarcinoma http://ow.ly/M9e830mZb8N

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma / metabolism*
Animals
Cell Line, Tumor
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic*
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Lung Neoplasms / metabolism*
MAP Kinase Kinase 5 / metabolism*
Male
Mice
Mice, Transgenic
Mitogen-Activated Protein Kinase 7 / metabolism*
Neoplasm Transplantation

Substances

MAPK7 protein, human
Mitogen-Activated Protein Kinase 7
MAP Kinase Kinase 5
MAP2K5 protein, human